Integra LifeSciences Holdings Corporation
General ticker "IART" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $986.4M (TTM average)
Integra LifeSciences Holdings Corporation follows the US Stock Market performance with the rate: 24.3%.
Estimated limits based on current volatility of 3.1%: low 15.48$, high 16.35$
Factors to consider:
- Total employees count: 4396 (+11.4%) as of 2024
- US accounted for 74.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Acquisition/divestiture risks, Regulatory and compliance, Labor/talent shortage/retention, Cybersecurity threats
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.12$, 18.85$]
- 2026-12-31 to 2027-12-31 estimated range: [9.69$, 19.71$]
Financial Metrics affecting the IART estimates:
- Positive: with PPE of 5.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Net income
- Positive: 19.24 < Shareholder equity ratio, % of 28.97 <= 42.59
- Positive: Industry inventory ratio change (median), % of -0.30 <= -0.16
- Positive: -0.02 < Operating cash flow per share per price, % of 5.17
- Negative: Inventory ratio change, % of 2.53 > 0.78
Short-term IART quotes
Long-term IART plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,541.57MM | $1,610.53MM | $1,635.24MM |
| Operating Expenses | $1,430.05MM | $1,582.12MM | $2,128.61MM |
| Operating Income | $111.53MM | $28.41MM | $-493.37MM |
| Non-Operating Income | $-30.46MM | $-46.65MM | $-70.13MM |
| Interest Expense | $51.38MM | $70.63MM | $86.25MM |
| R&D Expense | $104.19MM | $115.38MM | $98.97MM |
| Income(Loss) | $81.07MM | $-18.24MM | $-563.50MM |
| Taxes | $13.33MM | $-11.29MM | $-47.03MM |
| Net Income(Loss)* | $67.74MM | $-6.94MM | $-516.47MM |
| Stockholders Equity | $1,587.88MM | $1,545.28MM | $1,043.46MM |
| Inventory | $389.61MM | $429.09MM | $492.74MM |
| Assets | $3,781.99MM | $4,037.42MM | $3,602.00MM |
| Operating Cash Flow | $139.96MM | $129.38MM | $50.38MM |
| Capital expenditure | $66.86MM | $104.42MM | $81.44MM |
| Investing Cash Flow | $-94.18MM | $-390.81MM | $-108.06MM |
| Financing Cash Flow | $-229.93MM | $237.86MM | $28.34MM |
| Earnings Per Share** | $0.87 | $-0.09 | $-6.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.